Search and filter stories that passed editorial review. Evidence strength, regulatory status, and guideline position are shown separately and are never inferred from one another.
51 verified discoveries match your filters.
In the gynecologic expansion cohort of the first-in-human, phase 1 MYTHIC trial, the combination of lunresertib (a PKMYT1 inhibitor) and camonsertib (an ATR inhibitor) produced durable objective responses in heavily…
Primary source cited
Last reviewed
Eflornithine (Iwilfin), an oral drug that blocks an enzyme cancer cells use to make polyamines needed for growth, is the first FDA-approved therapy specifically intended to reduce relapse risk in…
Primary source cited
Last reviewed
In the randomized, phase 3 PANOVA-3 trial, adding Tumor Treating Fields (TTFields) -- a wearable device that emits alternating electric fields through skin-worn arrays -- to standard chemotherapy significantly extended…
Primary source cited
Last reviewed
In the dose-optimization portion of the now-terminated phase 2/3 REFRaME-O1 trial, the antibody-drug conjugate luveltamab tazevibulin produced objective responses in patients with platinum-resistant ovarian cancer expressing folate receptor alpha, at…
Primary source cited
Last reviewed
In the single-arm, phase 1/2 EPCORE NHL-1 trial, epcoritamab — a subcutaneously-injected bispecific antibody that physically brings a patient's own T-cells into contact with lymphoma cells — produced an objective…
Primary source cited
Last reviewed
In the randomized, phase 3 ENGOT-ov65/KEYNOTE-B96 trial, adding pembrolizumab to paclitaxel chemotherapy significantly improved BOTH progression-free survival (8.3 vs 7.2 months) AND overall survival (18.2 vs 14.0 months) in patients…
Primary source cited
Last reviewed
An investigational alpha-lactalbumin-targeted vaccine, developed by Anixa Biosciences with Cleveland Clinic, was reported to be safe and to induce a protocol-defined immune response in 74% of participants across all three…
Primary source cited
Last reviewed
In the randomized, open-label, phase 3 DeLLphi-304 trial, tarlatamab significantly extended overall survival compared with chemotherapy in patients with extensive-stage small cell lung cancer that had progressed after platinum-based chemotherapy…
Primary source cited
Last reviewed
In the MZL cohort of the single-arm, phase 2 TRANSCEND FL trial, lisocabtagene maraleucel -- a CD19-directed CAR T-cell therapy -- produced an intent-to-treat overall response rate of 84.4% and…
Primary source cited
Last reviewed
In the randomized, double-blind, placebo-controlled OlympiA trial, one year of adjuvant olaparib significantly improved invasive disease-free survival (primary publication) and, in a later analysis, significantly improved overall survival as well…
Primary source cited
Last reviewed